ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine

By The Science Advisory Board staff writers

ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.

The vaccine design is based on large datasets obtained during the analysis of ImmunoPrecise Antibodies' (IPA) SARS-CoV-2 therapeutic programs, which the firm has used to craft its spike protein variant vaccine candidates.

The candidates are combined with a novel class of synthetic carbohydrate derivatives with the final formulations aimed at high efficacy and low adverse effects, the firms said.

The preclinical study is ongoing at the Institute of Agrifood Research and Technology (IRTA) in Catalonia, Spain, and is focusing on a single, low-dose administration. In tandem, IPA and LiteVax are starting ex vivo assays, with study results expected by November 2020. From there, the companies will be able to prioritize which vaccine candidates to develop further.

However, it should be noted the companies are not making any claims that the vaccine has the ability to eliminate, cure, or contain SARS-CoV-2 at this time.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking